REG - C4X Discovery - Exercise of Options, Issue of Equity and TVR

C4X Discovery HoldingsAnnouncement

18/08/2023 13:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230818:nRSR8145Ja&default-theme=true

RNS Number : 8145J  C4X Discovery Holdings PLC  18 August 2023

C4X Discovery Holdings plc

("C4XD", "C4X Discovery" or the "Company")

Exercise of Options, Issue of Equity and Total Voting Rights

18 August 2023 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug
Discovery company, announces it has issued 107,500 ordinary shares of 1p
each in the Company ("New Ordinary Shares") following the exercise of options
by certain employees of the Company.

 

Admission and Total Voting Rights

Application has been made for the 107,500 New Ordinary Shares to be admitted
to trading on AIM and dealings are expected to commence on or around 8.00 a.m.
on 24 August 2023. The New Ordinary Shares will rank pari passu with the
existing ordinary shares.

 

Total Voting Rights

Following the issue of the New Ordinary Shares, the Company's issued share
capital now consists of 252,227,097 ordinary shares. Accordingly, the figure
of 252,227,097 may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in the Company under the FCA's
Disclosure Guidance and Transparency Rules.

 

Contacts

 C4X Discovery Holdings
 Mo Noonan, Communications                                 +44 (0)787 6444977

 Panmure Gordon (UK) Limited (NOMAD and Broker)
 Freddy Crossley, Emma Earl (Corporate Finance)            +44 (0)20 7886 2500

 Rupert Dearden (Corporate Broking)

 C4X Discovery Media - Consilium Strategic Communications
 Mary-Jane Elliott, Chris Gardner, Matthew Neal            +44 (0)203 709 5700

 

Notes to Editors:

 About C4X Discovery

C4X Discovery ("C4XD") is a pioneering Drug Discovery company, combining
scientific expertise with cutting-edge Drug Discovery technologies to
efficiently deliver world‑leading medicines.  We have a highly valuable and
differentiated approach to Drug Discovery through our enhanced candidate
molecule design and patient stratification capabilities, generating small
molecule drug candidates across multiple disease areas focused on
immuno-inflammation.  Our commercially attractive portfolio ranges from
early-stage target opportunities to late-stage Drug Discovery programmes and
we have three commercially partnered programmes with one candidate in clinical
development.

 

For more information visit us at www.c4xdiscovery.com
(http://www.c4xdiscovery.com/)  or follow us on twitter @C4XDiscovery.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEDZGMRMRDGFZM